Calpain inhibitor II
A cysteine protease inhibitor.
General information
Calpain inhibitor II is a peptide inhibitor of calpain, cathepsin L and cathepsin B proteases (Merck). It was also shown to inhibit SARS-CoV-2 3C-like protease in vitro (Ma et al., 2020) and thus likely acts dually (combined with cathepsin L inhibition) against SARS-CoV-2 infection (Hu et al., 2021).
Calpain inhibitor II on PubChem
Synonyms
N-Acetylleucyl-leucyl-methioninal
CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C=O)NC(=O)C
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
3CLpro Crystallization Small molecule Enzyme assay In vitro |
in vitro enzyme assay; crystallization; Vero 76 cells; SARS-CoV-2 strain USA-WA1/2020 | 20.51 | Inhibited SARS-CoV-2 3C-like protease with an IC50 of ca. 0.97 μM in vitro. Inhibited SARS-CoV-2 infection in primary CPE assay with an EC50 of ca. 2.07 μM and an SI of >48.3. |
Jun/15/2020 |
|
Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry
3CLpro Small molecule Enzyme assay In vitro |
in vitro enzyme assay; Vero E6 cells; MRC-5 human lung fibrobrast cells; HeLa cells | 4.10 | Manifests inhibitory activity (weaker than GC376) on the SARS-CoV-2 3C-like protease at non-cytotoxic concentrations. |
Sep/05/2020 |
|
Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development
3CLpro Cathepsin L Small molecule Enzyme assay In vitro |
in vitro enzyme assay | 4.10 | The compound inhibited the SARS-CoV-2 3C-like protease with IC50 of 743 nM and human cathepsin L with IC50 of 0.097 nM in vitro. |
Jan/27/2021 |
|
Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses
Biophysical assay Cathepsin L Enzyme assay In vitro Mechanism |
in vitro enzyme assay; in vitro biophysical assay; Vero cells; Caco-2 cells; (HIV-1) SARS-CoV-2 Spike pseudovirus | 4.61 | The compound inhibited cathepsin L in vitro with an IC50 of 0.3 nM. It neutralized SARS-CoV-2 pseudovirus in vitro with IC50s of ca. 10.15 μM and ca. 0.4 μM, alone or in the presence of 2 μM CP-100356 (an efflux pump inhibitor), respectively. The compound also inhibited SARS-CoV-2 replication in Caco-2 cells with an EC50 of ca. 6.37 μM and low cytotoxicity (CC50 >100 μM). |
Mar/01/2021 |
